Neogenesis Capital
Emerging managerBuilt from this firm's Form D filings. The firm files no SEC adviser report.
- HQ
- FL
NeoGenesis Capital invests in Colossal Biosciences and in companies built on and spun out of Colossal's platform, where AI meets synthetic biology. The firm aims to finance the industrialization of biology, turning genetic code into living products. Its leadership includes Co-Founder and Partner Peter H. Diamandis, MD, and Co-Founder and Managing Partner Yianni Psaltis, PhD.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Not stated | Not enough dated deals |
| Sectors | Biotech, Agtech, Synthetic biology | Not enough dated deals |
| Regions | Not stated | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| NeoGenesis Capital Fund I, LP Invests in Colossal Biosciences and companies built on its programmable biology platform, where superintelligence meets synthetic biology. Finances the industrialization of biology, turning genetic code into living products, through a concentrated single-ecosystem strategy. Inferred from the firm's website | 2026 | $33.08M (Form D) | Raising |
03 · People across funds
- Peter Diamandis
NeoGenesis Capital Fund I, LP (Named on Form D)
- Oliver Trevena, Head of Culture
- Peter H. Diamandis, MD, Co-Founder and Partner
- Yianni Psaltis, PhD, Co-Founder and Managing Partner
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://neogenesiscapital.com
- https://neogenesiscapital.com/
- https://neogenesiscapital.com/newsroom/neogenesis-capital-launches-fund/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026